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Angiogenesis is a rare event and tightly controlled under normal
physiological conditions, because normal cells secrete only low
levels of positive regulators and high levels of negative regulators
of angiogenesis (Bouck et al, 1996). Angiogenesis plays an
important role not only in wound healing, but also in cancer
development. Recently, the mechanism of cancer progression or
metastasis has been shown to be associated with angiogenesis
(Folkman et al, 1989; Folkman, 1995; Holmgren et al, 1995). The
onset of angiogenesis is believed to be an early event in carcino-
genesis and this process may facilitate cancer progression and
metastasis (Folkman et al, 1989). Vascular endothelial growth
factor (VEGF) has been identified as one of the factors that
increases the permeability (Senger et al, 1983; Ferrara and Henzel,
1989), and it is known to be the same as vascular permeabilty
factor (VMP) (Keck et al, 1989; Leung et al, 1989; Ferrara et al,
1991a; 1992). Four different isoforms with VEGF121, VEGF165,
VEGF189 and VEGF206 were identified by the alternating splicing
of mRNA (Ferrara et al, 1991b). Although VEGF contains a signal
peptide to direct secretion, only the two shorter forms (VEGF121
and VEGF165) are efficiently secreted. The two high molecular
weight forms (VEGF189 and VEGF206) seem to be mostly cell asso-
ciated (Ferrara et al, 1991b). VEGF secreted from tumour cells
causes the proliferation of surrounding endothelial cells through a
paracrine system (Brown et al, 1988) and associates closely with
dense vessels in tumour tissue. Tumour cells can easily invade
neovascular vessels because the basement membranes of these
vessels are immature.
VEGF expression was found in a wide variety of human carci-
nomas including brain (Takano et al, 1996), breast (Toi et al, 1996;
Yoshiji et al, 1996; Linderholm et al, 1998; Scott et al, 1998), lung
(Fontanini et al, 1997; 1999; Shibusa et al, 1998), oesophageal
(Inoue et al, 1997; Shimada et al, 1999), gastric (Maeda et al,
1995; 1999; Saito et al, 1999), colorectal (Takahashi et al, 1995;
1997; Ishigami et al, 1998; Kumar et al, 1998), pancreatic (Itakura
et al, 1997; Ikeda et al, 1999), hepatocellular (Suzuki et al, 1996),
renal and bladder (Brown et al, 1993; Takahashi et al, 1994;
O’Brien et al, 1995; O’Byrne et al, 1999), ovarian (Olson et al,
1994; Boocock et al, 1995; Abu-Jawdeh et al, 1996; Paley et al,
1997) and head and neck carcinomas (Eisma et al, 1997;
Moriyama et al, 1997; Salven et al, 1997; Maeda et al, 1998;
Burian et al, 1999; Neuchrist et al, 1999; Sauter et al, 1999), and
was suggested to play an important role in angiogenesis. VEGF
expression was reported to correlate with clinical parameters
including tumour size (Itakura et al, 1997; Kumar et al, 1998),
lymph-node metastasis (Maeda et al, 1995; Moriyama et al, 1997;
Kumar et al, 1998; Sauter et al, 1999), and prognosis (Maeda et al,
1995; Fontanini et al, 1997; Inoue et al, 1997; Linderholm et al,
1998; Saito et al, 1999, and so on), however, this relationship 
has not been consistent. Although all these studies were mostly
analysed only by immunohistochemistry, there have been no
reports of this relationship using Western blot, immunohistochem-
istry and reverse transcriptase-polymerase chain reaction (RT-
PCR), comparatively, in head and neck squamous cell carcinomas
(HNSCCs). The correlation between VEGF expression and
subsites of HNSCCs remains unknown.
The purpose of this study is to examine the level of VEGF
expression by Western blot in HNSCCs, and to confirm the precise
location of the cells expressing VEGF by immunohistochemistry;
to examine the form of VEGF mRNA by RT-PCR; and to examine
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characteristics and prognosis.
The data presented show that VEGF plays an important role in
lymph-node status and outcome in HNSCCs.
METHODS
Patients and materials
Sixty patients with HNSCCs without distant metastasis were
analysed. All patients were treated at the Department of
Otolaryngology, Hamamatsu University School of Medicine,
Hamamatsu, Japan. Clinical information including age, sex,
tumour size, lymph-node status, stage grouping, histologic grade,
and outcome was obtained from the clinical records. Primary
tumour size, lymph-node status, and stage grouping were classi-
fied according to the 1997 UICC criteria (Sobin and Witterkind,
1997). Two pieces of specimens were collected from the same
patients at surgery, one from tumour tissue and another from the
adjacent normal tissue. For confirming the specimen feasibility for
analysis, all specimens were divided into three parts for Western
blot, RT-PCR and histology.
Western blot
Thirty  µ g of the protein extract in a lysis buffer containing 
100 mM Tris (pH 7.4), 0.15 M NaCl, and 1% SDS was electro-
phoresed on a 12.5% SDS /polyacrylamide gel and transferred to a
Hybond-PVDF membrane (Amersham, Buckinghamshire,
England). Blots were first incubated in a blocking buffer
(Dulbecco’s PBS buffer containing 3% bovin serum albumin and
3% skimmed milk) for 1 h at room temperature, then the blots
were immunoblotted with the anti-human VEGF rabbit polyclonal
antibody (A-20: Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) at a dilution of 1:1500 at 4° C overnight. After rinsing the
blots with PBS, they were incubated with horseradish peroxidase
conjugated anti-rabbit IgG (Amersham) at a dilution of 1:1000 for
1 h at room temperature. After washing the blots, they were devel-
oped with a detection kit (ECL, Amersham). To confirm the result
of Western blot using A-20 antibody, we performed it using the
other anti-human VEGF antibody (A-147: Santa Cruz
Biotechnology Inc.) at a dilution of 1:1000 at 4° C overnight. The
optimized bands were analysed by a Model GS-700 Imaging
Densitometer (Bio-Rad, Hercules, CA, USA) and Molecular
Analyst Software/Macintosh (Bio-Rad). The density of VEGF
bands was divided into two groups (the ratio of tumour/normal
tissue, low < 3-fold; high ≥ 3-fold) by comparing it with the
density of the bands that we extracted from the accompanying
normal tissue. Actin (anti-actin antibody: 1–19, Santa Cruz
Biotechnology Inc., 1:1000 dilution) levels were analysed as
controls for protein loading. Tumours which showed high intensity
of VEGF expression for A-20 were considered to overexpress
VEGF.
RT-PCR
Total RNA was extracted using an ISOGEN kit (Nippon Gene,
Toyama, Japan) and RT-PCR was carried out using a RT-PCR high
kit (TOYOBO, Osaka, Japan), according to the manufacturers’
protocols. PCR primers were as follows: forward primer 
5′ -TCGGGCCTCCGAAACCATGA-3′ and reverse primer 5′ -
CCTGGTGAGAGATCTGGTTC-3′ (Weindel et al, 1992). These
primers can amplify the whole coding region of all known splicing
forms of VEGF mRNA. The PCR amplification cycle consisted of
denaturation at 95° C for 50 s, annealing at 57° C for 50 s, and
extension at 72° C for 70 s. This was done for 35 cycles. PCR
products were run on a 6% polyacrylamide gel and visualized by
ethidium bromide staining. G3PDH levels were analysed as
controls.
Immunohistochemistry
Five µ m sections were dewaxed with xylene, hydrated through
graded alcohols, and rehydrated in water. Sections were
microwaved in a citrate buffer (pH 6.0) three times for 5 min, and
endogenous peroxidase activity was blocked using 0.5% hydrogen
peroxide in methanol for 30 min. A 20% goat serum was applied
to the sections for 10 min as a blocking reagent to reduce non-
specific binding. A 1:1000 dilution of the monoclonal antibody
against VEGF protein (R&D, Abingdon, UK) was used. Sections
were incubated at 4° C overnight. They were incubated with the
biotinylated anti-mouse immunoglobulin rabbit antibody (DAKO,
Copenhagen, Denmark) for 30 min, followed by incubation with
streptavidin peroxidase reagents (Strept-ABComplex: DAKO) for
30 min. They were treated in diaminobenzidine solution for 5 min,
and then counterstained with haematoxylin.
Immunohistochemical evaluation
Immunohistochemical evaluation was performed by a pathologist
in a blind test (without knowledge of the clinical parameters and
outcome). At least 20 high-power fields from a single tissue
section were chosen at random, and 2000 tumour cells were
counted. Positive cells were stained dark brown on the cytoplasm.
The expression was considered high intensity if the expression
was noted in 10% or more tumour cells and was considered low
intensity if the expression was noted in fewer than 10% of the
tumour cells.
Statistical analysis
The association between discrete variables and VEGF expression
in western blot was tested by the Fisher’s exact probability test or
the Mann–Whitney U test. Cox’s proportional hazards regression
analysis that included age, sex, histologic grade, tumour size,
lymph-node status, stage grouping and VEGF expression was used
to identify the multivariate predictive value of the prognostic
factors. Disease-free survival (DFS) curves were constructed
using the method of Kaplan–Meier and tested by the log-rank test.
A significant difference was identified when the probability was
less than 0.05.
RESULTS
Clinical data of 60 patients with HNSCCs are summarized in
Tables 1 and 2. Western blot using two anti-VEGF antibodies (A-
20 and A-147) showed similar results. By the Western blot results
of A-20, we categorized the HNSCCs into two groups, high VEGF
expresser and low VEGF expressor (Table 1, Figure 1A). Western
blot analysis revealed high VEGF expression in 26 patients (43%)
776 H Mineta et al
British Journal of Cancer (2000) 83(6), 775–781 © 2000 Cancer Research Campaign(average ± SD, range: 10.02 ± 6.73, 3.1–22.1) and low VEGF
expression in 34 patients (57%) (0.99 ± 0.61, 0.01–1.8). High
VEGF expressors were found in 71% (5/7) of oropharyngeal
carcinoma, 56% (9/16) of laryngeal carcinoma, 45% (9/20) of oral
carcinoma, 40% (2/5) of hypopharyngeal carcinoma, and 8%
(1/12) of maxillary carcinoma. The incidence of maxillary carci-
nomas was significantly lower than that of others (P = 0.006).
RT-PCR analysis showed that in 22 patients two forms of tran-
scripts were detected, which encoded for VEGF121 and VEGF165, and
in 38 patients they were not (Figure 1B). The result of RT-PCR was
significantly correlated with that of Western blot (P = 0.00007).
Immunohistochemical analysis showed that VEGF positive
reactivity was found in 35 patients, and not in 25 patients. The
positive cells of expressing VEGF were almost all tumour cells.
Tumour infiltrating lymphocytes, endothelial cells, and fibroblasts
also showed positive reactivity, although its contribution to the
whole tissue was minor (Figure 2). The result of immunohisto-
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Figure 1 Vascular endothelial growth factor (VEGF) protein and mRNA
analyses. A: 42 kD (VEGF); B: 17 kD (Actin); C: 650 bp (VEGF165); D: 
520 bp (VEGF121); E: 450 bp (G3PDH). Lanes 1 and 2: tumour area and
normal area in the patient with tongue carcinoma, lanes 3 and 4: tumour area
and normal area in the patient with hypopharyngeal carcinoma, lanes 5 and
6: tumour area and normal area in the patient with laryngeal carcinoma,
lanes 7 and 8: tumour area and normal area in the patient with
hypopharyngeal carcinoma, and lane M: molecular weight marker of RT-
PCR. (A) VEGF protein was demonstrated by Western blot in lanes 1, 3, 5,7,
and 8. The density of lane 7 was 3.2-fold higher than that of lane 8. Actin
levels were controlled for protein loading. (B) VEGF mRNA was showed by
RT-PCR in lanes 1, 3, 5, 7, and 8. The 650 bp and 520 bp encoded
VEGF165 and VEGF121, respectively. Two longer forms (VEGF206 and
VEGF189) were not detected. G3PDH levels were used as controls
Table 1 VEGF expression by Western blot and primary site in 60 patients
with head and neck squamous cell carcinomas
Primary High VEGF expressors Low VEGF expressors
site (n = 26) (n = 34)
Oral cavity 9 (45%) 11 (55%)
Larynx 9 (56%) 7 (44%)
Maxillary sinus 1 (8%) 11 (92%)
Oropharynx 5 (71%) 2 (29%)
Hypopharynx 2 (40%) 3 (60%)
Table 2 VEGF expression by Western blot according to clinicopathological characteristics and VEGF
RT-PCR and VEGF immunostaining analyses
Patient and tumour High VEGF expressors Low VEGF expressors P-value
characteristics (n = 26) (n = 34)
Age (Mean) 37–90 (63) 21–79 (60) NSa
Sex (Men:Women) 23:3 23:11 NSa
Histologic grade
Poorly 3 4 NSb
Moderately 8 11
Well 15 19
Tumour size
T1 2 3 NSb
T2 11 11
T3 7 6
T4 6 14
Lymph-node status
N0 4 21 0.0009b
N1 7 6
N2 10 7
N3 5 0
Stage
I1 2 N S b
II 3 9
III 4 5
IV 18 18
VEGF RT-PCR
Positive 17 5 0.00007a
Negative 9 29
VEGF immunostaining
Positive 23 12 0.00006a
Negative 3 22
aFisher’s exact probability test; bMann–Whitney U test; NS = not significantchemistry was significantly correlated with that of Western blot 
(P = 0.00006).
Table 2 shows the clinical differences between high VEGF
expressors and low VEGF expressors. The VEGF expression was
significantly correlated with lymph-node status (P = 0.0009), but
not with age, sex, histologic grade, tumour size, and stage
grouping. High VEGF expressors displayed more aggressive
lymph-node metastasis.
Multivariate analysis using Cox’s hazard model revealed that
VEGF expression and stage grouping were independent predictors
for the DFS (P = 0.045 and 0.041, respectively). However, sex,
histologic grade, tumour size, and lymph-node status were not
(Table 3). Kaplan–Meier curve (Figure 3) demonstrated that the 2-
year DFS rate of high VEGF expressors (30%) was significantly
lower than that of low VEGF expressors (78%) (P = 0.01).
DISCUSSION
We studied VEGF expression in 60 patients with HNSCCs. High
VEGF expressors by Western blot were associated with the
progression of lymph-node spread, which were correlated with
poor DFS.
We measured the level of VEGF protein in tumour tissue
compared with adjacent normal tissue by Western blot, confirmed
tumour cells expressing VEGF by immunohistochemistry, and
compared the result of Western blot with that of RT-PCR or IHC.
These methods need a small number of specimens, and detecting
both mRNA and protein levels by the different materials and
methods could guarantee the accuracy of the results. Because
VEGF mRNA and proteins are being produced, transported, and
degradated in situ, a single method such as measuring only mRNA
or protein may fail to detect its production. Although the cut-off
point between high and low VEGF expressors is optional in this
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Figure 2 Haematoxylin-eosin (HE) staining and vascular endothelial growth factor (VEGF) immunostaining of tumour tissue from the patient with tongue
carcinoma. (A) Well differentiated squamous cell carcinoma of the tongue shows invasive growth (HE staining) (original magnification × 40). (B) VEGF
immunostaining of tumour tissue in the same lesion as A (× 25). The positive reactivity of almost tumour cells and vascular endothelial cells are shown (× 40).
(C) VEGF immunostaining of tumour tissue in high magnification. The cytoplasm of the tumour cells are stained positive. The fibroblasts, vascular endothelial
cells (arrow), and lymphocytes around the tumour are also stained positive (× 100). (D) No cells are stained using PBS as the first antibody instead of anti-
VEGF antibody (negative control) (× 25)
Table 3 Risk factors affecting disease-free survival (DFS) rate, determined
by Cox’s proportional hazards model
Variable Relative risk 95% Cl P-value
Sex
Men vs Women 0.885 0.324–2.419 0.812
Histologic grade
Poorly vs others 0.594 0.215–1.644 0.316
Tumour size
1,2 vs 3,4 0.572 0.177–1.843 0.349
Lymph-node status
(–) vs (+) 0.719 0.274–1.884 0.502
Stage
1,2 vs 3,4 8.425 1.092–8.086 0.041
VEGF expression
Negative vs Positive 0.424 0.184–0.980 0.045analysis of Western blot, it clearly divided into high VEGF expres-
sors and low VEGF expressors. The result of Western blot analysis
significantly correlated with that of RT-PCR according to this cut-
off point criterion. Twenty-two patients out of 26 high VEGF
expressors by Western blot showed two isoforms of transcripts by
RT-PCR. This suggests that VEGF protein may come from newly
synthesized mRNA, and not from the proteolytic cleavage of
precursor proteins which were transported from other places.
However, four patients showed high VEGF protein expression
without VEGF mRNA expression. This discrepancy may be due to
the sensitivity of antibody and sampling errors. The mRNA and
the protein may be examined in different tumour areas where
hypoxic normal tissue or activated macrophages secreting VEGF
are contained. The detected two isoforms of transcripts showed the
shorter secreted types which had biological activity. All high
VEGF expressors showed VEGF-positive reactivity in immuno-
staining. Although fibroblasts, endothelial cells and tumour
infiltrating cells were also positively stained, their contributions
were minor compared to the tumour cells.
We found high VEGF expressors in 43% in HNSCC. The varied
expression may depend on the differences in the source of the
specimen, the method of analysis and the organ specificity. The
immunohistochemical analysis revealed the positivity in a wide
range, because of the differences in the criteria. The incidence of
high VEGF expressors was greater in renal (Takahashi et al, 1994)
or lung (Fontanini et al, 1997) carcinomas than in oesophageal
(Inoue et al, 1997; Shimada et al, 1999) or gastric (Maeda et al,
1999; Saito et al, 1999) carcinomas. VEGF is generally expressed
in malignant tumours, and is rarely expressed in benign tumours or
normal tissues except for alveolar cells in the lung, podocytes and
mesangium cells in the glomerulus, and cortical cells in the adrenal
gland (Brown et al, 1992; 1993). This may suggest that the
tumours originating from these organs are more likely to express
VEGF than other organs. HNSCCs include heterogeneous carci-
nomas and could have different biological activities in each loca-
tion and histology. In fact, maxillary squamous cell carcinomas
exhibited the low incidence of high VEGF expressors.
The process of metastasis may take place in two stages: pre-
vascular and vascular (Weidner et al, 1991). In the prevascular 
stage, marginal tumour cells locally invade host stroma
surrounding the primary tumour without vascular invasion,
which is associated with limited growth. In the vascular phase,
tumour cells enter blood vessels or lymphatic vessels, which is
associated with rapid growth or metastasis (Macchiarini et al,
1992). Although neovascularization is necessary to become the
vascular phase, it is controlled by the balance of positive and
negative regulators. VEGF does not stimulate the growth of
tumour cells directly, but leads to the growth and increase of
permeability of endothelial cells. VEGF serves to induce 
neovascularization around tumour cells and promotes extravasa-
tion of plasma fibrinogen, leading to the alteration of the tumour
extracellular matrix (Eisma et al, 1997) and promoting metastasis
by breaking down the extracellular matrix in the tumour
microenvironment. These may be an important role of VEGF on
tumour cells.
We found that VEGF expression was associated with lymph-
node status. The previous studies in HNSCC (Eisma et al, 1997;
Moriyama et al, 1997; Sauter et al, 1999) revealed that VEGF
expression was concerned with tumour aggressiveness. Sauter et
al (1999) documented that VEGF staining was found in the
majority of advanced primary SCCs and lymph-node metastases,
whereas dysplasia, carcinoma in situ, or early SCCs did not show
intense immunostaining. However, some studies reported that
there was no association of VEGF expression with tumour size or
lymph-node status in HNSCC (Salven et al, 1997; Maeda et al,
1998; Neuchrist et al, 1999). Our study supported Sauter’s
results that the higher VEGF expressors were associated with
lymph-node metastasis. Regional lymph-node spread is less
frequently seen from tumours of the maxillary sinus clinically,
which may be attributed to the low incidence of high VEGF
expressors. Some studies of the microvessel density (Gasparini et
al, 1993; Williams et al, 1994; Murray et al, 1997; Sauter et al,
1999) revealed that tumour microvessel density was correlated
with tumour progression and recurrence. Williams et al (1994)
reported that patients with > 4 mm of tumour depth and > 10%
Factor VIII tumour staining had a 100% rate of recurrence, and
that only angiogenesis was found to be an independent predictor
of nodal metastasis, while others (Dray et al, 1995; Zätterström
et al, 1995; Moriyama et al, 1997; Neuchrist et al, 1999) failed to
find any association. This inconsistency may depend on: the
small number of patients analysed; the heterogeneous group of
tumours with different primary sites and of different stages; the
different areas of each histologic sections (i.e. marginal or
central of the tumour); the wide range of immunohistochemical
positivity.
Multivariate analysis revealed VEGF expression and stage
grouping were independent predictors for DFS, however there is
controversy whether VEGF expression influences the prognosis.
The 2-year DFS of high VEGF expressors (30%) was significantly
lower than that of low VEGF expressors (78%). Although this
study was limited to a small number of patients and a short dura-
tion of follow-up, it suggests that high VEGF expressors may 
need further adjunctive therapy to control lymph-node metastasis.
VEGF expression may help us: to make the decision of prophylac-
tive neck dissection; to select the patients to take the anti-angio-
genetic therapy; and to confirm the pharmacological effect of
anti-angiogenetic drugs. Future studies need to investigate the
relationship between VEGF expression and recurrence or metas-
tasis in a large number of patients with HNSCCs.
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Figure 3 The Kaplan–Meier curve for disease-free survival (DFS) showed
the 2-year DFS rates of vascular endothelial growth factor (VEGF) high
expressors and VEGF low expressors. The 2-year DFS rate of VEGF high
expressors (30%) was significantly lower than that of VEGF low expressors
(78%) (P = 0.0008)In summary VEGF was highly expressed in 43% in HNSCCs.
High VEGF expressors were significantly correlated with lymph-
node spread, and their prognosis was significantly worse than that
of low VEGF expressors.
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